Cubist Systematic Strategies LLC Makes New Investment in Phreesia, Inc. $PHR

Key Points

• Cubist Systematic Strategies LLC has acquired 30,265 shares of Phreesia, Inc. valued at approximately $774,000, indicating growing institutional interest in the company.
• Key analysts have upgraded Phreesia's stock ratings, with price targets revised upwards, including a raise from $28.00 to $35.00 by KeyCorp.
• Phreesia reported a Q2 earnings per share (EPS) of $0.01, exceeding analyst estimates, along with a 14.9% revenue increase year-over-year.

Cubist Systematic Strategies LLC acquired a new stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,265 shares of the company's stock, valued at approximately $774,000. Cubist Systematic Strategies LLC owned about 0.05% of Phreesia at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. KBC Group NV bought a new position in Phreesia in the first quarter worth about $74,000. CWM LLC raised its stake in Phreesia by 994.9% in the first quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after buying an additional 3,671 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in Phreesia by 53.0% in the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after buying an additional 1,825 shares in the last quarter. GAMMA Investing LLC raised its stake in Phreesia by 10,605.7% in the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock worth $145,000 after buying an additional 5,621 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new position in Phreesia in the fourth quarter worth about $163,000. 92.10% of the stock is owned by institutional investors.

Insider Activity

In related news, General Counsel Allison C. Hoffman sold 1,245 shares of the firm's stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $26.89, for a total value of $33,478.05. Following the sale, the general counsel owned 136,978 shares in the company, valued at approximately $3,683,338.42. This trade represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of the firm's stock in a transaction that occurred on Thursday, June 26th. The stock was sold at an average price of $27.67, for a total transaction of $77,531.34. Following the completion of the sale, the director owned 22,037 shares in the company, valued at $609,763.79. This represents a 11.28% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,292 shares of company stock valued at $3,295,323. Company insiders own 5.50% of the company's stock.

Phreesia Stock Down 5.0%

Shares of NYSE:PHR traded down $1.28 during trading on Friday, reaching $24.20. 1,348,119 shares of the stock traded hands, compared to its average volume of 1,074,343. The stock has a 50-day moving average of $28.12 and a two-hundred day moving average of $26.48. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $32.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 2.12. The stock has a market cap of $1.45 billion, a P/E ratio of -57.62 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The firm had revenue of $117.26 million for the quarter, compared to analysts' expectations of $116.39 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The business's revenue for the quarter was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. As a group, sell-side analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Raymond James Financial set a $33.00 price target on shares of Phreesia and gave the stock an "outperform" rating in a research note on Friday, September 5th. KeyCorp upped their price objective on shares of Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a report on Monday, July 14th. DA Davidson upgraded shares of Phreesia to a "strong-buy" rating in a report on Monday. Stephens restated an "overweight" rating and issued a $32.00 price objective on shares of Phreesia in a report on Wednesday, September 3rd. Finally, Truist Financial upped their price objective on shares of Phreesia from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, Phreesia presently has a consensus rating of "Buy" and a consensus price target of $34.08.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.